Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.12 Consensus Price Target from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $5.12.

Several equities analysts have commented on GUTS shares. Craig Hallum assumed coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 target price on the stock. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings raised shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.69 on Thursday. The firm has a market capitalization of $108.68 million, a P/E ratio of -0.53 and a beta of 2.32. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. The firm’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.72. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $2.44.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.23. As a group, research analysts anticipate that Fractyl Health will post -0.6 EPS for the current year.

Insider Activity at Fractyl Health

In other news, Director William Bradley acquired 68,493 shares of the stock in a transaction dated Wednesday, June 10th. The stock was bought at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the purchase, the director directly owned 84,622 shares of the company’s stock, valued at $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ian Sheffield acquired 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, with a total value of $25,550.00. Following the acquisition, the director owned 35,000 shares in the company, valued at $25,550. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 171,493 shares of company stock worth $127,150 over the last ninety days. 8.52% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Fractyl Health during the second quarter valued at $31,000. Accredited Investors Inc. acquired a new position in shares of Fractyl Health during the first quarter worth $46,000. Scientech Research LLC bought a new stake in shares of Fractyl Health in the third quarter worth $49,000. FNY Investment Advisers LLC grew its stake in shares of Fractyl Health by 84.3% in the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after purchasing an additional 29,920 shares during the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health in the third quarter valued at $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.